Cargando…

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Detalles Bibliográficos
Autores principales:	Hofheinz, Ralf, Lorenzen, Sylvie, Bohlmann, Michael K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341063/ https://www.ncbi.nlm.nih.gov/pubmed/37444443 http://dx.doi.org/10.3390/cancers15133333

Ejemplares similares

Epigenetics of asthma—the field continues to evolve
por: Rastogi, Deepa
Publicado: (2022)

Traumatic brain injury: the research continues with higher data quality evolving!
por: Maegele, Marc
Publicado: (2023)

Treatment of early-stage HER2+ breast cancer—an evolving field
por: Ferreira, Arlindo R, et al.
Publicado: (2015)

The journey continues ... and so we evolve
por: Nayak, Barun Kumar
Publicado: (2008)

The International Dental Journal Continues to Evolve
por: Lamster, Ira B.
Publicado: (2021)

HER2 testing in gastric cancer: results of a German expert meeting
por: Lordick, Florian, et al.
Publicado: (2017)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Ventricular Assist Devices: an Evolving Field
por: Kubrusly, Luiz Fernando
Publicado: (2019)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Nonsuicidal self-injury: a rapidly evolving global field
por: Lewis, Stephen P., et al.
Publicado: (2015)

A perspective on the evolving field of vitreoretinal diseases
por: Sengupta, Sabyasachi
Publicado: (2018)

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
por: Merx, Kirsten, et al.
Publicado: (2016)

Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices
por: Abraham, Jame, et al.
Publicado: (2020)

HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
por: Hou, Yanjun, et al.
Publicado: (2023)

Virology and Immunology Researchers Evolve with the Viruses We Study
por: Russell, Rodney S.
Publicado: (2020)

Thymic Epithelial Tumors: An Evolving Field
por: Kuhn, Elisabetta, et al.
Publicado: (2023)

What do we learn from HER2-positive breast cancer genomic profiles?
por: Theillet, Charles
Publicado: (2010)

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
por: Norton, Nadine, et al.
Publicado: (2013)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
por: Jankowitz, Rachel C, et al.
Publicado: (2012)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Arthritis Research & Therapy evolves: online only from 2011
por: Hrynaszkiewicz, Iain, et al.
Publicado: (2010)

BMC Blood Disorders becomes BMC Hematology: evolving along with the hematology field
por: Chap, Christna
Publicado: (2013)

Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors
por: Yazici, Cemal, et al.
Publicado: (2017)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases
por: Lin, N.U.
Publicado: (2022)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

From the Editor’s Desk: the Evolving Journey of Engaging Patients as Research Partners
por: Frosch, Dominick L.
Publicado: (2022)

Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
por: McGee, Sharon F., et al.
Publicado: (2022)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Metformin in breast cancer - an evolving mystery
por: Camacho, Laura, et al.
Publicado: (2015)

The evolving landscape in advanced penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2015)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
por: Harbeck, Nadia
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_864jo5jh45869joh494fp6gusa